According to Sylvie Rouen-van Beek, a SNP (single nucleotide polymorphism) alters the activity of a protein to a variable degree: function may be reduced, increased or abolished. Clinical reasoning therefore rests not on the polymorphism alone, but on its phenotypic impact, modulated by epigenetics, environment and lifestyle. A heterozygous profile (one variant allele) often produces context-dependent symptoms and moderately increased nutritional needs; a homozygous profile (two variant alleles) produces clearer symptoms and markedly higher needs.
FUT2: mucosa, microbiota and gut susceptibility
The FUT2 gene codes for a fucosyltransferase involved in the fucosylation of glycoproteins in the intestinal mucosa (around 72 % secretors, 28 % non-secretors). In secretors, it favours an environment suited to bifidobacteria, a better maintained barrier and strong local immunity. Non-secretors show a more structural dysbiosis, a microbiota poor in bifidobacteria, greater permeability and a more marked vulnerability to infection (with, in return, natural resistance to certain noroviruses and rotaviruses). Supports mentioned: 2'-fucosyllactose (which stands in for the fucosylated oligosaccharides that are not synthesised), mucin precursors, butyrate, bifidobacteria and Lactobacillus strains, collagen for epithelial repair, and acacia gum.
MTHFR: the methylation cascade
MTHFR converts dietary folate into 5-MTHF, the active form, which allows homocysteine to be converted into methionine and then SAMe, the universal methyl donor, to be produced. The C677T and A1298C variants can reduce activity by 70 to 75 %. A shortfall in SAMe affects the neurotransmitters, DNA, hepatic metabolism and the phospholipids; a shortfall in 5-MTHF promotes the build-up of homocysteine, inflammation and poorer regeneration of BH4 (a cofactor for dopamine and serotonin). One critical point in preconception and pregnancy: an excess of standard folic acid can block conversion to the active folate. Supports mentioned: 5-MTHF, methylcobalamin, P5P and R5P (active B forms), betaine (TMG), which supports the BHMT pathway independently of MTHFR, and magnesium, a cofactor for methylation reactions.
COMT: the catecholamine thermostat
COMT inactivates dopamine, noradrenaline and adrenaline by methylation (and also metabolises catechol oestrogens), mainly in the prefrontal cortex, the liver and the adrenal glands. There are three profiles: fast (GG), intermediate (AG) and slow (AA). Fast COMT breaks catecholamines down quickly, sometimes with fatigue, low mood and lack of motivation; SAMe and TMG then meet an increased need for methyl groups. Slow COMT accumulates catecholamines (anxiety, rumination, hypervigilance) and sometimes tolerates methyl donors poorly: the approach stays cautious and gradual, particularly for vitamins B9 and B12. Supports mentioned: active forms of the B vitamins, choline, myo-inositol, magnesium, and glutathione cofactors (glycine, taurine, sulforaphane).
DIO2: cellular energy and T4 to T3 conversion
DIO2 takes part in the local conversion of T4 into T3 within the tissues. Because the deficit is intracellular, a standard work-up (TSH, T4, T3) can stay normal while functional tissue hypothyroidism is present: persistent fatigue, sensitivity to cold, brain fog, mitochondrial dysfunction, a rise in reactive species and a drop in ATP. TC heterozygotes (around 35 %) have a reduced adaptive response to exertion and to cold; TT homozygotes (5 to 10 %) show intolerance to intense exertion. Supports mentioned: selenium, zinc, taurine, NAC, glycine, acetyl-carnitine, sulforaphane, and omega 3.
Why polymorphisms potentiate one another
Variants do not simply add up, they potentiate one another: MTHFR 677T reduces methylation, a fast COMT drains the SAMe that is produced, FUT2 non-secretor status sets up dysbiosis and reduces absorption of B12 and folate, and an impaired DIO2 weighs on tissue energy. The clinical picture then runs deeper than the sum of the variants, often mixing fatigue, brain fog, digestive symptoms, premenstrual syndrome, emotional stress and repeated intolerances. Reading the genotype makes that picture coherent.
When to consider testing, and its limits
Testing earns its place in the face of unexplained multisystem symptoms, treatment-resistant chronic fatigue, persistent mood, sleep or concentration problems, recurrent dysbiosis, permeability that will not settle, a relevant family history, or poor tolerance of the usual supplements. It points to the genetic terrain and the pathways that may be compromised, but not to the real clinical severity, the precise dose, or the weight of epigenetics. It replaces neither the biological work-up nor the clinical history.
The logic: work around the block, do not correct the genome
Three approaches complement one another, according to Sylvie Rouen-van Beek: supplying the end product directly (5-MTHF for MTHFR, 2'-fucosyllactose for FUT2, active B vitamins for COMT, selenium and zinc for DIO2); supporting the enzyme's micro-environment when the enzyme is still present but working at reduced capacity; and reducing demand on the blocked pathway (avoiding standard folic acid, activating the BHMT pathway with TMG, supporting the oxidative and mitochondrial terrain, and acting on downstream consequences such as inflammation, intestinal permeability or neurotransmitter deficits).
Putting it into practice with Simplycure
To turn a genetic profile into a readable protocol, from the choice of active forms through to sequencing and gradual dosing, Simplycure brings the protocols and products of more than 300 brands together on a single platform. Create your practitioner account to compare and recommend in a few clicks.
